Stockscreener 앱 받기
20.34
1.47%
0.29
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Can Arcutis Biotherapeutics Inc. hit a new high this monthEarnings Overview Summary & Free High Return Stock Watch Alerts - newser.com
Sentiment analysis tools applied to Arcutis Biotherapeutics Inc.Market Growth Report & Daily Market Momentum Tracking - newser.com
Is Arcutis Biotherapeutics Inc. stock safe for conservative investors2025 Winners & Losers & Long-Term Growth Plans - newser.com
Should you wait for a breakout in Arcutis Biotherapeutics Inc.Oil Prices & Free Risk Controlled Daily Trade Plans - newser.com
How to interpret RSI for Arcutis Biotherapeutics Inc. stockQuarterly Portfolio Summary & Weekly High Potential Alerts - newser.com
Has Arcutis Biotherapeutics Inc. found a price floorWeekly Trade Recap & Fast Gain Swing Alerts - newser.com
What the charts say about Arcutis Biotherapeutics Inc. todayPortfolio Update Summary & Reliable Intraday Trade Plans - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cutsTrade Signal Summary & Real-Time Volume Triggers - newser.com
Arcutis Biotherapeutics Hits New 52-Week High of $21.55 - Markets Mojo
Arcutis Biotherapeutics reaches milestone recognized by Nasdaq - Traders Union
Wealth Enhancement Advisory Services LLC Purchases Shares of 15,666 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Is Arcutis Biotherapeutics Inc. stock bottoming out2025 Price Momentum & Free Growth Oriented Trading Recommendations - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 1-Year HighStill a Buy? - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD By Investing.com - Investing.com Australia
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD - Investing.com
Mizuho raises Arcutis Biotherapeutics stock price target to $26 on Zoryve sales - Investing.com
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 - BioSpace
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $26 - 富途牛牛
FDA approves ZORYVE cream for atopic dermatitis in young children By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $90,260.16 in Stock - MarketBeat
Arcutis Biotherapeutics Hits New 52-Week High of $21.30 - Markets Mojo
FDA Approves Roflumilast Cream 0.05% for Atopic Dermatitis in Children 2 to 5 - Drug Topics
Arcutis Biotherapeutics stock rises after FDA approves eczema cream for young children - Investing.com
ARQT: FDA Approves ZORYVE Cream for Young Children's Atopic Dermatitis - GuruFocus
FDA approves ZORYVE cream for atopic dermatitis in young children - Investing.com
Arcutis Biotherapeutics Announces FDA Approval of ZORYVE® Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5 - Quiver Quantitative
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 (2025-10-06) - Seeking Alpha
Fishman Jay A Ltd. MI Purchases 23,000 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
What drives Arcutis Biotherapeutics Inc stock priceMarket Sentiment Extremes & Ride the Wave of Market-Beating Growth - earlytimes.in
Is Arcutis Biotherapeutics Inc. stock reversal real or fakeJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Arcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor Interest - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.2% Following Insider Selling - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2% After Insider Selling - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 10,000 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 24,261 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 20,739 Shares - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics reports inducement grants under Nasdaq Listing Rule - MarketScreener
94,500 RSUs Granted — Arcutis Reports Inducement Grants to 12 New Hires, Vesting Over Four Years - Stock Titan
Will Arcutis Biotherapeutics Inc. stock split attract more investorsOptions Play & Weekly Chart Analysis and Guides - newser.com
Arcutis Biotherapeutics Achieves 101.39% Stock Surge, Establishing It as a Multibagger Performer - Markets Mojo
Arcutis Biotherapeutics Hits New 52-Week High of $20.10, Up 162% - Markets Mojo
AMI Asset Management Corp Sells 94,839 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Revenues Not Telling The Story For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) After Shares Rise 27% - simplywall.st
Q4 2025 FDA Preview: 10 Decisions to Watch - HCPLive
Arcutis Biotherapeutics Hits New 52-Week High of $19.36 - Markets Mojo
Arcutis Biotherapeutics Hits Day High with Strong 7.29% Intraday Surge - Markets Mojo
Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Reviewing BioMarin Pharmaceutical (NASDAQ:BMRN) & Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year - MSN
ARQTArcutis Biotherapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week HighWhat's Next? - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 18.17 USD By Investing.com - Investing.com Nigeria
0.95%
자본화:
|
볼륨(24시간):